Prepopik and Truvada approved

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

Researchers outline individual peripheral arterial disease burden as well as the most at-risk patient populations and treatment recommendations.

Availability will vary by state, and a pharmacy professor says cost barriers can keep families from getting vaccinated.

Darren Mensch, PharmD, BCPS, BCACP, provides evidence-based nuance regarding the emergence of mRNA vaccine technology and health care’s understanding of it.

Study findings tie continuous glucose monitoring measures to elevated cardiovascular risk in adults without diabetes.

The once daily tablet is expected to reach US patients in October 2026.

The label expansion adds patients 12 years of age and older to the once daily alopecia areata indication.

Pharmacist and public health expert Jennifer Hammons, PharmD, DrPH, discusses pharmacy as essential infrastructure amid rural pharmacies persistently being overlooked.